Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

China Pharma Holdings (CPHI) Convertible Debt (2021 - 2022)

China Pharma Holdings filings provide 2 years of Convertible Debt readings, the most recent being $4.8 million for Q2 2022.

On a quarterly basis, Convertible Debt changed N/A to $4.8 million in Q2 2022 year-over-year; TTM through Jun 2022 was $4.8 million, a N/A change, with the full-year FY2021 number at $5.2 million, changed N/A from a year prior.
Convertible Debt hit $4.8 million in Q2 2022 for China Pharma Holdings, down from $5.0 million in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $5.2 million in Q4 2021 to a low of $4.8 million in Q2 2022.